Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures; Guidance for Industry and Food and Drug Administration Staff; Availability, 34161-34163 [2023-11260]

Download as PDF 34161 Federal Register / Vol. 88, No. 102 / Friday, May 26, 2023 / Notices committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2023–11327 Filed 5–25–23; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. You can also obtain copies of the proposed collection of information by emailing infocollection@ acf.hhs.gov. Identify all emailed requests by the title of the information collection. SUPPLEMENTARY INFORMATION: Description: State and Tribal title IV– E agencies are required to report AFCARS case-level information on all children in foster care and children who have been adopted or placed in a ADDRESSES: Submission for OMB Review: Adoption and Foster Care Analysis and Reporting System (AFCARS) (OMB #0970–0422) Children’s Bureau, Administration for Children and Families, Department of Health and Human Services (HHS). ACTION: Request for public comments. AGENCY: The Children’s Bureau (CB), the Administration for Children and Families (ACF) is requesting a threeyear extension of the data information collection for the Adoption and Foster Care Analysis and Reporting System (AFCARS) that was implemented as part of the AFCARS final rule published in May 2020 (85 FR 28410). There are no proposed changes to the data SUMMARY: information collection published as the regulation in May 2020. The estimated time per response related to record keeping has been revised since the previous published notice (88 FR 16449) due to feedback from the State and Tribal reporting agencies. DATES: Comments due within 30 days of publication. OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Total number of respondents Instrument AFCARS—Recordkeeping ................................................... AFCARS—Reporting ........................................................... Estimated Total Annual Burden Hours: 1,180,590. Authority: Section 479 of the Social Security Act and 45 CFR 1355.44–45. 69 69 3 6 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2022–D–0737] Mary B. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2023–11291 Filed 5–25–23; 8:45 am] BILLING CODE 4184–25–P ddrumheller on DSK120RN23PROD with NOTICES1 Total number of responses per respondent Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures; Guidance for Industry and Food and Drug Administration Staff; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ‘‘Non-Clinical SUMMARY: VerDate Sep<11>2014 18:14 May 25, 2023 Jkt 259001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 guardianship with title IV–E agency involvement. The data collected will inform policy decisions, program management, and responses to Congressional and Departmental inquiries. Specifically, the data are used for short/long-term budget projections, trend analysis, child and family service reviews, and to target areas for improved technical assistance. The data will provide information on the number of children in foster care, the reasons they enter and exit care, and how to prevent their unnecessary placement in foster care. Specifically, the data include information about children who enter foster care, their entries and exits, placement details, and foster/adoptive parent information. This extension request is unrelated to any potential new regulatory activity that may occur subsequently. This request is for public comment on the burden calculations. It does not seek comment on the data elements that have been through the rulemaking process. Respondents: Title IV–E State and Tribal Child Welfare Agencies. Annual Burden Estimates The following annual burden estimates have been updated to reflect feedback received from the States and Tribes after the first notice published on May 15, 2023 (88 FR 16449). This feedback encouraged ACF to increase the estimated hours per response for recordkeeping. Average burden hours per response 17,076 17 Total burden hours 3,534,732 7,038 Annual burden hours 1,178,244 2,346 Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures.’’ This guidance document provides recommendations that may help manufacturers comply with the special controls related to non-clinical performance data for gynecologic and general laparoscopic power morcellation containment systems (‘‘tissue containment systems’’). Tissue containment systems are used to enable isolation and containment of tissue during a power morcellation procedure performed following a laparoscopic procedure for the excision of benign tissue that is not suspected to contain malignancy. E:\FR\FM\26MYN1.SGM 26MYN1 34162 Federal Register / Vol. 88, No. 102 / Friday, May 26, 2023 / Notices The announcement of the guidance is published in the Federal Register on May 26, 2023. ADDRESSES: You may submit either electronic or written comments on Agency guidances at any time as follows: DATES: ddrumheller on DSK120RN23PROD with NOTICES1 Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2022–D–0737 for ‘‘Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. VerDate Sep<11>2014 18:14 May 25, 2023 Jkt 259001 • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). An electronic copy of the guidance document is available for download from the internet. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance. Submit written requests for a single hard copy of the guidance document entitled ‘‘Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures’’ to the Office of Policy, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993–0002. Send one selfaddressed adhesive label to assist that office in processing your request. PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 FOR FURTHER INFORMATION CONTACT: Prasanna Hariharan, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 62, Rm. 2222, Silver Spring, MD 20993–0002, 301–796–2689 or by email at prasanna.hariharan@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background This guidance document provides recommendations that may help manufacturers comply with the special controls related to non-clinical performance data for gynecologic and general laparoscopic power morcellation containment systems (‘‘tissue containment systems’’). Tissue containment systems are used to enable isolation and containment of tissue during a power morcellation procedure performed following a laparoscopic procedure for the excision of benign tissue that is not suspected to contain malignancy. This guidance recommends non-clinical test methods that may help manufacturers meet the non-clinical performance data requirements identified in the special controls codified in § 884.4050(b)(4) (21 CFR 884.4050(b)(4)) (for gynecologic use) and § 878.4825(b)(4) (21 CFR 878.4825(b)(4)) (for general use), and also includes other non-clinical testing recommendations to support a 510(k) submission/substantial equivalence determination. The recommendations in this guidance are based on FDA’s experience evaluating the safety and effectiveness of tissue containment systems. However, manufacturers may use alternative approaches and provide different documentation so long as their approach and documentation satisfy premarket submission requirements in applicable statutory provisions and regulations. A notice of availability of the draft guidance appeared in the Federal Register of June 21, 2022 (87 FR 36859). FDA considered comments received and revised the guidance as appropriate in response to the comments, including a clarification that material permeability testing is recommended to aid in demonstrating substantial equivalence but is not required in the special controls in § 884.4050(b)(4) and § 878.4825(b)(4); specifying that aged samples may be subject to accelerated or real time aging; and indicating that a manufacturer conducting final finished testing of a tissue containment system with multiple device sizes may use the worst-case size sample(s), but, if doing so, should provide a justification for the E:\FR\FM\26MYN1.SGM 26MYN1 Federal Register / Vol. 88, No. 102 / Friday, May 26, 2023 / Notices choice of worst-case size sample(s) in its submission. This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on ‘‘Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures.’’ It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Electronic Access Persons interested in obtaining a copy of the guidance may do so by downloading an electronic copy from use the document number GUI00019015 and complete title to identify the guidance you are requesting. III. Paperwork Reduction Act of 1995 While this guidance contains no new collection of information, it does refer to previously approved FDA collections of information. Therefore, clearance by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501– 3521) is not required for this guidance. The previously approved collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations, guidance, and forms have been approved by OMB as listed in the following table: 21 CFR part or guidance Topic 807, subpart E .......................................................................................................... ‘‘Requests for Feedback and Meetings for Medical Device Submissions: The QSubmission Program’’. Premarket notification ............................. Q-submissions ........................................ Dated: May 23, 2023. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2023–11260 Filed 5–25–23; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [Docket No. FDA–2019–D–0934] Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products; Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled ‘‘Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products.’’ The guidance represents the current thinking of FDA on adjusting for covariates in randomized clinical trials for drugs and biological products. The guidance discusses general recommendations for performing covariate adjustment, recommendations for performing covariate adjustment using linear models, and recommendations for performing covariate adjusting using nonlinear models. The guidance is intended to facilitate covariate SUMMARY: VerDate Sep<11>2014 18:14 May 25, 2023 Jkt 259001 OMB control No. 0910–0120 0910–0756 adjustment in the analysis of randomized clinical trials of drugs and biological products and to clarify recommendations for its use. The guidance finalizes the revised draft guidance entitled ‘‘Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products’’ issued on May 21, 2021. comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). The announcement of the guidance is published in the Federal Register on May 26, 2023. Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2019–D–0934 for ‘‘Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be DATES: Food and Drug Administration ddrumheller on DSK120RN23PROD with NOTICES1 the internet. A search capability for all Center for Devices and Radiological Health guidance documents is available at https://www.fda.gov/medical-devices/ device-advice-comprehensiveregulatory-assistance/guidancedocuments-medical-devices-andradiation-emitting-products. This guidance document is also available at https://www.regulations.gov, https:// www.fda.gov/regulatory-information/ search-fda-guidance-documents. Persons unable to download an electronic copy of ‘‘Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures’’ may send an email request to CDRHGuidance@fda.hhs.gov to receive an electronic copy of the document. Please 34163 You may submit either electronic or written comments on Agency guidances at any time as follows: ADDRESSES: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\26MYN1.SGM 26MYN1

Agencies

[Federal Register Volume 88, Number 102 (Friday, May 26, 2023)]
[Notices]
[Pages 34161-34163]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-11260]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-D-0737]


Non-Clinical Performance Assessment of Tissue Containment Systems 
Used During Power Morcellation Procedures; Guidance for Industry and 
Food and Drug Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of a final guidance entitled ``Non-Clinical 
Performance Assessment of Tissue Containment Systems Used During Power 
Morcellation Procedures.'' This guidance document provides 
recommendations that may help manufacturers comply with the special 
controls related to non-clinical performance data for gynecologic and 
general laparoscopic power morcellation containment systems (``tissue 
containment systems''). Tissue containment systems are used to enable 
isolation and containment of tissue during a power morcellation 
procedure performed following a laparoscopic procedure for the excision 
of benign tissue that is not suspected to contain malignancy.

[[Page 34162]]


DATES: The announcement of the guidance is published in the Federal 
Register on May 26, 2023.

ADDRESSES: You may submit either electronic or written comments on 
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2022-D-0737 for ``Non-Clinical Performance Assessment of Tissue 
Containment Systems Used During Power Morcellation Procedures.'' 
Received comments will be placed in the docket and, except for those 
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. 
and 4 p.m., Monday through Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    An electronic copy of the guidance document is available for 
download from the internet. See the SUPPLEMENTARY INFORMATION section 
for information on electronic access to the guidance. Submit written 
requests for a single hard copy of the guidance document entitled 
``Non-Clinical Performance Assessment of Tissue Containment Systems 
Used During Power Morcellation Procedures'' to the Office of Policy, 
Center for Devices and Radiological Health, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver 
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist 
that office in processing your request.

FOR FURTHER INFORMATION CONTACT: Prasanna Hariharan, Center for Devices 
and Radiological Health, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 62, Rm. 2222, Silver Spring, MD 20993-0002, 301-
796-2689 or by email at [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    This guidance document provides recommendations that may help 
manufacturers comply with the special controls related to non-clinical 
performance data for gynecologic and general laparoscopic power 
morcellation containment systems (``tissue containment systems''). 
Tissue containment systems are used to enable isolation and containment 
of tissue during a power morcellation procedure performed following a 
laparoscopic procedure for the excision of benign tissue that is not 
suspected to contain malignancy. This guidance recommends non-clinical 
test methods that may help manufacturers meet the non-clinical 
performance data requirements identified in the special controls 
codified in Sec.  884.4050(b)(4) (21 CFR 884.4050(b)(4)) (for 
gynecologic use) and Sec.  878.4825(b)(4) (21 CFR 878.4825(b)(4)) (for 
general use), and also includes other non-clinical testing 
recommendations to support a 510(k) submission/substantial equivalence 
determination. The recommendations in this guidance are based on FDA's 
experience evaluating the safety and effectiveness of tissue 
containment systems. However, manufacturers may use alternative 
approaches and provide different documentation so long as their 
approach and documentation satisfy premarket submission requirements in 
applicable statutory provisions and regulations.
    A notice of availability of the draft guidance appeared in the 
Federal Register of June 21, 2022 (87 FR 36859). FDA considered 
comments received and revised the guidance as appropriate in response 
to the comments, including a clarification that material permeability 
testing is recommended to aid in demonstrating substantial equivalence 
but is not required in the special controls in Sec.  884.4050(b)(4) and 
Sec.  878.4825(b)(4); specifying that aged samples may be subject to 
accelerated or real time aging; and indicating that a manufacturer 
conducting final finished testing of a tissue containment system with 
multiple device sizes may use the worst-case size sample(s), but, if 
doing so, should provide a justification for the

[[Page 34163]]

choice of worst-case size sample(s) in its submission.
    This guidance is being issued consistent with FDA's good guidance 
practices regulation (21 CFR 10.115). The guidance represents the 
current thinking of FDA on ``Non-Clinical Performance Assessment of 
Tissue Containment Systems Used During Power Morcellation Procedures.'' 
It does not establish any rights for any person and is not binding on 
FDA or the public. You can use an alternative approach if it satisfies 
the requirements of the applicable statutes and regulations.

II. Electronic Access

    Persons interested in obtaining a copy of the guidance may do so by 
downloading an electronic copy from the internet. A search capability 
for all Center for Devices and Radiological Health guidance documents 
is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. This guidance document is also 
available at https://www.regulations.gov, https://www.fda.gov/regulatory-information/search-fda-guidance-documents. Persons unable to 
download an electronic copy of ``Non-Clinical Performance Assessment of 
Tissue Containment Systems Used During Power Morcellation Procedures'' 
may send an email request to [email protected] to receive an 
electronic copy of the document. Please use the document number 
GUI00019015 and complete title to identify the guidance you are 
requesting.

III. Paperwork Reduction Act of 1995

    While this guidance contains no new collection of information, it 
does refer to previously approved FDA collections of information. 
Therefore, clearance by the Office of Management and Budget (OMB) under 
the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521) is not 
required for this guidance. The previously approved collections of 
information are subject to review by OMB under the PRA. The collections 
of information in the following FDA regulations, guidance, and forms 
have been approved by OMB as listed in the following table:

------------------------------------------------------------------------
     21 CFR part or guidance             Topic          OMB control No.
------------------------------------------------------------------------
807, subpart E..................  Premarket                    0910-0120
                                   notification.
``Requests for Feedback and       Q-submissions......          0910-0756
 Meetings for Medical Device
 Submissions: The Q-Submission
 Program''.
------------------------------------------------------------------------


    Dated: May 23, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-11260 Filed 5-25-23; 8:45 am]
BILLING CODE 4164-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.